Provided by Tiger Trade Technology Pte. Ltd.

Tarsus Pharmaceuticals, Inc.

78.09
-0.9400-1.19%
Post-market: 78.090.00000.00%19:30 EDT
Volume:710.97K
Turnover:55.55M
Market Cap:3.43B
PE:-72.14
High:79.10
Open:78.67
Low:77.33
Close:79.03
52wk High:91.53
52wk Low:51.57
Shares:43.88M
Float Shares:35.64M
Volume Ratio:1.21
T/O Rate:1.99%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0824
EPS(LYR):-1.5900
ROE:-13.68%
ROA:-5.48%
PB:9.88
PE(LYR):-49.11

Loading ...

Tarsus Pharmaceuticals (TARS) Losses Narrow In Q1 2026 Challenging Bearish Narratives

Simply Wall St.
·
May 08

Tarsus to Participate in Upcoming Investor Conferences

GlobeNewswire
·
May 08

Tarsus Pharmaceuticals Earnings Call Signals Durable Growth

TIPRANKS
·
May 07

Tarsus Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 07

Tarsus Q1 FY26 net loss narrows to $7 million; net product sales rise 85% to $145.4 million

Reuters
·
May 07

Tarsus Pharmaceuticals Q1 EPS $(0.16) Beats $(0.33) Estimate, Sales $162.054M Beat $148.422M Estimate

Benzinga Earnings
·
May 07

BRIEF-Tarsus Pharmaceuticals Q1 EPS USD -0.16

Reuters
·
May 07

Tarsus Pharmaceuticals Inc - Reaffirms FY2026 Xdemvy Net Product Sales Guidance of $670 Mln-$700 Mln

THOMSON REUTERS
·
May 07

Tarsus Pharmaceuticals Q1 Revenue USD 145.387 Million VS. Ibes Estimate USD 148.4 Million

THOMSON REUTERS
·
May 07

Tarsus Pharmaceuticals - Reaffirmed Full-Year 2026 Guidance of $670-700 Million of Xdemvy Net Product Sales

THOMSON REUTERS
·
May 07

LifeSci Capital Sticks to Their Buy Rating for Tarsus Pharmaceuticals (TARS)

TIPRANKS
·
May 06

Tarsus Pharmaceuticals Inc expected to post a loss of 37 cents a share - Earnings Preview

Reuters
·
May 05

Buy Rating Reaffirmed on XDEMVY as Inventory Dynamics Seen as Transient and $88 Price Target Remains Unchanged

TIPRANKS
·
May 04

Tarsus Pharmaceuticals Price Target Maintained With a $88.00/Share by HC Wainwright & Co.

Dow Jones
·
May 04

Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026

GlobeNewswire
·
Apr 30

Bank of America Securities Sticks to Its Buy Rating for Tarsus Pharmaceuticals (TARS)

TIPRANKS
·
Apr 29

Tarsus Pharmaceuticals announces annual shareholder meeting via webcast

Reuters
·
Apr 29

Oppenheimer Adjusts Price Target on Tarsus Pharmaceuticals to $98 From $105, Maintains Outperform Rating

MT Newswires Live
·
Apr 24

Tarsus Pharmaceuticals : Oppenheimer Cuts Target Price to $98 From $105

THOMSON REUTERS
·
Apr 24

Shoucheng Invests in Embodied AI Leader TARS to Deepen Robotics Push

TIPRANKS
·
Apr 16